<DOC>
	<DOCNO>NCT00996684</DOCNO>
	<brief_summary>The purpose study determine whether microplasmin give intravitreal injection effective safe treatment wet age-related macular degeneration ( AMD ) patient focal vitreomacular adhesion ( VMA )</brief_summary>
	<brief_title>Study Intravitreal Microplasmin Relieving Vitreo-Macular Adhesion Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description>The human vitreous gel undergoes progressive liquefaction age . Concurrent process vitreous liquefaction , weaken adhesion vitreoretinal interface cortical vitreous gel inner limit lamina . Posterior vitreous detachment ( PVD ) separation cortical vitreous get inner limit lamina . PVD usually sudden event liquefy vitreous center vitreous body burst hole posterior vitreous cortex dissects residual cortex gel away inner limit lamina . If residual vitreoretinal traction around break , process may induce tear retina turn result rhegmatogenous retinal detachment , macular hole , cystoid macular edema . The importance vitreous progression diabetic retinopathy may also extend beyond tractional consideration . For example , believe vitreous serf scaffold new vessel formation may also contribute molecular imbalance lead retinopathy progression . Therefore , total PVD , release vitreoretinal traction well potential mechanism , may beneficial various vitreoretinal disease neovascular AMD . Vitreomacular adhesion ( VMA ) exudative ( wet ) AMD may associate poor prognosis patient AMD . This trial primarily aim show release VMA induce microplasmin , proteolytic enzyme , patient wet AMD , microplasmin safe patient w/ neovascular ( wet ) AMD . Secondary endpoint assessment improve AMD outcome .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Fibrinolysin</mesh_term>
	<criteria>Male female subject age 50 year old Presence focal vitreomacular adhesion see OCT BCVA 20/800 good nonstudy eye Presence active choroidal neovascular membrane Written inform consent obtain subject prior inclusion trial Subjects previously receive microplasmin Subjects vitreous hemorrhage vitreous opacification precludes adequate examination investigation study eye Patient uncontrolled glaucoma include IOP &gt; 25 mm Hg Subjects vitrectomy retinal detachment aphakic highly myopic ( &gt; 8.0 D ) study eye Subjects pregnant childbearing potential utilizing acceptable form contraception . Acceptable method include intrauterine device , oral , implanted injected contraceptive , barrier method spermicide . Subjects , Investigator 's view , complete visit investigation Patient PDT intravitreal injection last 10 day . Patients examiner opinion need intravitreal injection next 10 day ( apart microplasmin ) . Patients participate investigational drug trial past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Wet age relate macular degeneration ( AMD )</keyword>
	<keyword>Wet AMD</keyword>
	<keyword>Vitreomacular adhesion ( VMA )</keyword>
	<keyword>Vitreomacular traction ( VMT )</keyword>
	<keyword>Neovascular age relate macular degeneration</keyword>
</DOC>